Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment

[1] Lok AS(2012)Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable Ann Intern Med 156 743-745

[2] Ward JW(2012)Management of rheumatic disease with comorbid HBV or HCV infection Nat Rev Rheumatol 8 348-711

[3] Perrillo RP(2015)Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 61 703-393

[4] Vassilopoulos D(2012)Rheumatology meets hepatology in 2012: a clinician’s guideline for TNF inhibitors in hepatitis B/C virus carriers Expert Opin Biol Ther 12 391-8

[5] Calabrese LH(2020)Moderate risk of hepatitis B virus reactivation in HBsAg(-)/HBcAb(+) carriers receiving rituximab for rheumatoid arthritis Sci Rep 10 2456-219

[6] Di Bisceglie AM(2019)Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: a narrative review J Microbiol Immunol Infect 52 1-1725

[7] Lok AS(2015)American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy Gastroenterology 148 215-276

[8] Martin P(2011)Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy Ann Rheum Dis 70 1719-686

[9] Jansen TL(2020)Efficacy of tocilizumab treatment in severely ill COVID-19 patients Crit Care 24 524-1782

[10] Mulder C(2020)Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm Chest S0012-3692 34901-1-1599

[1] Lok AS(2012)Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable Ann Intern Med 156 743-745

[2] Ward JW(2012)Management of rheumatic disease with comorbid HBV or HCV infection Nat Rev Rheumatol 8 348-711

[3] Perrillo RP(2015)Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 61 703-393

[4] Vassilopoulos D(2012)Rheumatology meets hepatology in 2012: a clinician’s guideline for TNF inhibitors in hepatitis B/C virus carriers Expert Opin Biol Ther 12 391-8

[5] Calabrese LH(2020)Moderate risk of hepatitis B virus reactivation in HBsAg(-)/HBcAb(+) carriers receiving rituximab for rheumatoid arthritis Sci Rep 10 2456-219

[6] Di Bisceglie AM(2019)Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: a narrative review J Microbiol Immunol Infect 52 1-1725

[7] Lok AS(2015)American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy Gastroenterology 148 215-276

[8] Martin P(2011)Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy Ann Rheum Dis 70 1719-686

[9] Jansen TL(2020)Efficacy of tocilizumab treatment in severely ill COVID-19 patients Crit Care 24 524-1782

[10] Mulder C(2020)Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm Chest S0012-3692 34901-1-1599